A Potential Antitumor Effect of Dendritic Cells Fused with Cancer Stem Cells in Hepatocellular Carcinoma

HCC stem cells were reported as posttreatment residual tumor cells that play a pivotal role in tumor relapse. Fusing dendritic cells (DCs) with tumor cells represents an ideal approach to effectively activate the antitumor immunity in vivo. DC/HCC stem cell vaccine provides a potential strategy to g...

Full description

Saved in:
Bibliographic Details
Main Authors: Ye-Bin Pang (Author), Jian He (Author), Bi-Yu Cui (Author), Sheng Xu (Author), Xi-Lei Li (Author), Man-Ya Wu (Author), Rong Liang (Author), Yan Feng (Author), Xing Guo (Author), Xue-Hui Zhang (Author), Xiao-Ling Luo (Author)
Format: Book
Published: Hindawi Limited, 2019-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8f44b5c9e6d24d6085a013a8ceb17b56
042 |a dc 
100 1 0 |a Ye-Bin Pang  |e author 
700 1 0 |a Jian He  |e author 
700 1 0 |a Bi-Yu Cui  |e author 
700 1 0 |a Sheng Xu  |e author 
700 1 0 |a Xi-Lei Li  |e author 
700 1 0 |a Man-Ya Wu  |e author 
700 1 0 |a Rong Liang  |e author 
700 1 0 |a Yan Feng  |e author 
700 1 0 |a Xing Guo  |e author 
700 1 0 |a Xue-Hui Zhang  |e author 
700 1 0 |a Xiao-Ling Luo  |e author 
245 0 0 |a A Potential Antitumor Effect of Dendritic Cells Fused with Cancer Stem Cells in Hepatocellular Carcinoma 
260 |b Hindawi Limited,   |c 2019-01-01T00:00:00Z. 
500 |a 1687-966X 
500 |a 1687-9678 
500 |a 10.1155/2019/5680327 
520 |a HCC stem cells were reported as posttreatment residual tumor cells that play a pivotal role in tumor relapse. Fusing dendritic cells (DCs) with tumor cells represents an ideal approach to effectively activate the antitumor immunity in vivo. DC/HCC stem cell vaccine provides a potential strategy to generate polyclonal immune response to multiple tumor stem cell antigens including those yet to be unidentified. To assess the potential capacity of DC/HCC stem cell vaccines against HCC, CD90+HepG2 cells were sorted from the HCC cell line HepG2. DC and CD90+HepG2 and DC and HepG2 fused cells were induced by polyethylene glycol (PEG). The influence of fusion cells on proliferation and immunological function transformation of lymphocytes was assessed by FCM and ELISA assay, respectively. The cytotoxicity assay of specific fusion cell-induced CTLs against HepG2 was conducted by CytoTox 96 Non-Radioactive Cytotoxicity Assay kit in vitro. At last, the prevention of HCC formation in vivo was described in a mouse model. The results of FCM analysis showed that the proportion of CD90+HepG2 cells in the spheral CD90+HepG2 enriched by suspension sphere culture was ranging from 98.7% to 99.5%, and 57.1% CD90+HepG2/DC fused cells were successfully constructed. The fusion cells expressed a higher level of costimulatory molecules CD80, CD83, CD86, and MHC-I and MHC-II molecules HLA-ABC and HLA-DR than did immature DCs (P<0.05). And the functional analysis of fusion cell-induced CTLs also illustrated that CD90+HepG2/DC fusion cells showed a greater capacity to activate proliferation of lymphocytes in vitro (P<0.05). The CD90+HepG2/DC-activated CTLs had a specific killing ability against CD90+HepG2 cells in vivo. These results suggested that CD90+HepG2/DC fusion cells could efficiently stimulate T lymphocytes to generate specific CTLs targeting CD90+HepG2 cells. It might be a promising strategy of immunotherapy for HCC. 
546 |a EN 
690 |a Internal medicine 
690 |a RC31-1245 
655 7 |a article  |2 local 
786 0 |n Stem Cells International, Vol 2019 (2019) 
787 0 |n http://dx.doi.org/10.1155/2019/5680327 
787 0 |n https://doaj.org/toc/1687-966X 
787 0 |n https://doaj.org/toc/1687-9678 
856 4 1 |u https://doaj.org/article/8f44b5c9e6d24d6085a013a8ceb17b56  |z Connect to this object online.